Solute Carriers (SLCs) account for approximately 2% of known human coding genes, and play diverse roles in human physiology. Despite ~100 SLCs being implicated in human disease, they also remain one of the most under-studied groups of genes in human biology.
Genetic variants in one such uncharacterized SLC, namely SLC16A11, were recently identified as one of the largest genetic risk signals for type 2 diabetes (T2D).
I will describe the functional follow-up to the genetic discovery of SLC16A11, which led to the identification of two distinct molecular mechanisms that link SLC16A11 dysfunction to disease.
This work suggests that SLC16A11 is a promising therapeutic target for T2D.
Solute Carriers (SLCs) account for approximately 2% of known human coding genes, and play diverse roles in human physiology. Despite ~100 SLCs being implicated in human disease, they also remain one of the most under-studied groups of genes in human biology.
Genetic variants in one such uncharacterized SLC, namely SLC16A11, were recently identified as one of the largest genetic risk signals for type 2 diabetes (T2D).
I will describe the functional follow-up to the genetic discovery of SLC16A11, which led to the identification of two distinct molecular mechanisms that link SLC16A11 dysfunction to disease.
This work suggests that SLC16A11 is a promising therapeutic target for T2D.
Solute Carriers (SLCs) account for approximately 2% of known human coding genes, and play diverse roles in human physiology. Despite ~100 SLCs being implicated in human disease, they also remain one of the most under-studied groups of genes in human biology.
Genetic variants in one such uncharacterized SLC, namely SLC16A11, were recently identified as one of the largest genetic risk signals for type 2 diabetes (T2D).
I will describe the functional follow-up to the genetic discovery of SLC16A11, which led to the identification of two distinct molecular mechanisms that link SLC16A11 dysfunction to disease.
This work suggests that SLC16A11 is a promising therapeutic target for T2D.
